Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report

Key Terms

universal registration document regulatory

A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.

annual financial report financial

A company's annual financial report is a comprehensive, year‑end packet that shows its money story — income, expenses, assets and debts — along with a plain‑language summary of results and risks. Think of it as a yearly report card plus a health check: it helps investors judge whether the business grew, made money, managed debts and faces any red flags, so they can decide to buy, hold or sell shares.

corporate governance report regulatory

A corporate governance report is a document that explains how a company's leaders are chosen, how decisions are made, and what checks are in place to prevent missteps—think of it as the company’s rulebook and report card on internal oversight. Investors use it to judge how well a company is managed, how risks are controlled, and whether leaders’ incentives align with shareholder interests; stronger governance usually means lower risk of surprises and better long-term value.

statutory auditors regulatory

Statutory auditors are independent, legally required professionals who examine a company's financial statements and records to confirm they are accurate and comply with law. Think of them as an impartial inspector or referee who checks the bookkeeping and internal controls; their reports give investors confidence that reported profits, losses and risks are reliable and help detect errors, fraud or accounting problems that could affect a company’s value.

form 20-f regulatory

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

securities and exchange commission regulatory

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2025 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2025 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 1^st, 2026. It can be downloaded (in French) on the Company’s website and on the AMF’s website.

The following documents are incorporated into the Universal Registration Document:

• the annual financial report,
• the annual management report,
• the corporate governance report provided for under Article L. 225-37 of the French Commercial Code,
• the report of Statutory Auditors.

The Company also announced today the filing of its Form 20-F annual report for the year ending December 31, 2025 with the United States Securities and Exchange Commission (“SEC”) on April 1^st, 2026. It can be also be accessed on the Company’s website and on the SEC’s website.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260402761027/en/

investors & Media Relations



Innate Pharma

Stéphanie Cornen

stephanie.cornen@innate-pharma.fr



Investor Relations

investors@innate-pharma.fr



Media

communication@innate-pharma.fr

Source: Innate Pharma SA